Osaka Bioscience Institute
Records under this name other than patents Osaka Bioscience Institute holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Osaka Bioscience Institute
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,198,427 | Animal repellent Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,658,390 | Method for detecting muscle degenerative diseases, and method for determining therapeutic efficacy on the diseases Formerly held Lapsed on the fee record Ended Feb 25, 2026 · From the USPTO record | Lapsed on the fee record | Ended Feb 25, 2026 | From the USPTO record |
| US 6,348,334 | DNA encoding Fas ligand Formerly held Term ended Term ended Feb 19, 2019 · From the USPTO record | Term ended | Term ended Feb 19, 2019 | From the USPTO record |
| US 7,128,905 | Method of treating graft versus host disease by administration of a Fas antagonist Lapsed on the fee record Ended Oct 31, 2018 · From the USPTO record | Lapsed on the fee record | Ended Oct 31, 2018 | From the USPTO record |
| US 6,270,998 | DNA coding for human cell surface antigen Formerly held Term ended Term ended Aug 7, 2018 · From the USPTO record | Term ended | Term ended Aug 7, 2018 | From the USPTO record |
| US 7,760,925 | Method for automatically detecting degenerated regions in stained thin section slides Lapsed on the fee record Ended Jul 20, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jul 20, 2018 | From the USPTO record |
| US 6,605,705 | Prostaglandin D synthase-specific monoclonal antibody Formerly held Term ended Term ended Apr 28, 2018 · From the USPTO record | Term ended | Term ended Apr 28, 2018 | From the USPTO record |
| US 7,622,554 | FAS ligand derived polypeptides Formerly held Term ended Term ended Sep 8, 2015 · From the USPTO record | Term ended | Term ended Sep 8, 2015 | From the USPTO record |
| US 7,238,718 | Method for Treating Myolytic Disease and Method for Screening Antimyolytic Agent Lapsed on the fee record Ended Jul 3, 2015 · High confidence | Lapsed on the fee record | Ended Jul 3, 2015 | High confidence |
| US 7,858,346 | Regeneration and Neogenesis of Retinal Visual Cell-Expressing OTX2 Protein Formerly held Lapsed on the fee record Ended Dec 28, 2014 · High confidence | Lapsed on the fee record | Ended Dec 28, 2014 | High confidence |